Video Game-based Exercise for Persons With Parkinson's Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03689764 |
Recruitment Status :
Completed
First Posted : September 28, 2018
Last Update Posted : October 18, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Parkinson Disease | Other: interactive video game-based exercise Other: no intervention | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effects of Interactive Video Game-based Exercise on Balance of Persons With Parkinson's Disease |
Actual Study Start Date : | June 2014 |
Actual Primary Completion Date : | October 2017 |
Actual Study Completion Date : | January 15, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Group A
Group A underwent interactive video game-based exercise for the initial 6 weeks, with no treatment in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
|
Other: interactive video game-based exercise
Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks. Other: no intervention Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks. |
Experimental: Group B
Group B had no intervention in the first 6 weeks and then received interactive video game-based exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
|
Other: interactive video game-based exercise
Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks. Other: no intervention Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks. |
- Change of Berg Balance Scale (BBS) [ Time Frame: 15 minutes/session; measured at weeks 0, 6, and 12 of the experiment ]Participants perform a series of 14 functional balance tasks, such as maintaining a quiet stance, sitting-to-stand, shifting weight and reaching, turning in place, standing on one leg, and maintaining a tandem stance. The performance of each task is scored on a 5-point ordinal scale (from 0 to 4). A score of 0 denotes the inability of the participant to perform the task, and a score of 4 denotes that the participant can complete the task based on a preset criterion. The highest possible score is 56 . Previous studies have shown that inter-rater and intra-rater reliability of BBS is high in elderly people and stroke patients.
- Change of 36-Item Short-Form Health Survey (SF-36) [ Time Frame: 15 minutes/session; measured at weeks 0, 6, and 12 of the experiment ]The 8 scales in SF 36 including Physical function (PF), Role-physical (RP), Bodily pain (BP), General health (GH), Vitality (VT), Social Function (SF), Role-Emotional (RE), Mental Health (MH) . Neuromuscular condition is one of the most frequently studied disease with use of SF-36 .
- Change of Modified Falls Efficacy Scale (MFES) [ Time Frame: 10 minutes/session; measured at weeks 0, 6, and 12 of the experiment ]The MFES is a 14-item rating scale questionnaire that contains the original 10-activity Falls Efficacy Scale and 4 additional activities. Items are rated from 0 (not confident at all) to 10 (completely confident), and the highest possible score is 140.
- Change of Multidirectional Reach Test (MDRT) [ Time Frame: 10 minutes/session; measured at weeks 0, 6, and 12 of the experiment ]The participants were required to reach in the forward, left and right directions. For the forward-reaching direction, the participants began by raising both arms to the shoulder level. They were then instructed to reach forward as far as they could without moving their feet, while maintaining the end-range position for 3 seconds. A soft measuring tape fixed to the wall was used to measure the start and end positions of the middle finger to measure the reaching distance. The same instructions were provided for the lateral reaching tests, except that the participants lifted only their right or left arm when reaching in the right or left directions, respectively. Three trials were performed in each direction, and the reaching distance was normalized according to the measured foot length.
- Change of Maximum Step Length (MSL) test [ Time Frame: 10 minutes/session; measured at weeks 0, 6, and 12 of the experiment ]The participants performed the MSL test in the forward, lateral and backward directions. For the forward direction test, the participants assumed the starting position by crossing their arms over their chest. They were then instructed to take a maximum step forward with one leg without moving the other, and then to return to the starting position with a single step.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- medical diagnosis of idiopathic Parkinson's Disease
- independent community ambulatory individuals
- capable of giving informed and written consent (Mini-Mental Status Examination (MMSE)>23)
Exclusion Criteria:
- the other neurological conditions such as dementia, and stroke, or if they have arthritis, vision impairment,
- cardiovascular disease that impair walking, or diabetic and uremic individuals, or if they were unable to walk without assistance.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03689764
Taiwan | |
Taipei Medical university Hospital | |
Taipei, Taiwan |
Principal Investigator: | Chien-Hung Lai, MD PhD | Taipei Medical University Hospital |
Responsible Party: | Lai chien hung, Professor, Taipei Medical University Hospital |
ClinicalTrials.gov Identifier: | NCT03689764 |
Other Study ID Numbers: |
201311032 |
First Posted: | September 28, 2018 Key Record Dates |
Last Update Posted: | October 18, 2019 |
Last Verified: | October 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases |